Stay updated on Chemo Plus Pembrolizumab in Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Chemo Plus Pembrolizumab in Breast Cancer Clinical Trial page.

Latest updates to the Chemo Plus Pembrolizumab in Breast Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange Detected- Revision: v3.4.2 was added and Revision: v3.4.1 was removed. These are global UI/operational updates and do not modify study details or records on the page.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a site-wide notice about government funding lapse and NIH operating status. Updated the page version from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedThe page shows a glossary toggle and includes updated labels in the Study Record Dates and footer, such as 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0'.SummaryDifference0.2%

- Check64 days agoChange DetectedThe study's location information was reorganized under a new Locations section with California and Oregon listed within it, replacing the previous separate California Locations and Oregon Locations sections. The revision number was updated to v3.3.3 and the HHS Vulnerability Disclosure footer was removed.SummaryDifference0.3%

- Check85 days agoChange DetectedThe page footer now displays 'Revision: v3.3.2' and removes 'Revision: v3.3.1'—a minor administrative change that does not affect the study data, eligibility criteria, or scheduling. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check92 days agoChange DetectedThe Publications section now notes that PubMed publications are automatically filled and may not be about the study, and the page revision is updated to v3.3.1.SummaryDifference0.1%

Stay in the know with updates to Chemo Plus Pembrolizumab in Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Chemo Plus Pembrolizumab in Breast Cancer Clinical Trial page.